RoMS could supply an alternative of CDS for the treatment of PD and the study indicates a potential advantage of RoMS for the treatment of mild and advanced PD patient in combination with L-DOPA.
BTK inhibition has been shown to be a potential approach to treat rheumatoid arthritis. We sought to develop an oral small molecule inhibitor in China market for rheumatoid arthritis. Our medchem group discovered a novel PCC WX486 which demonstrated superior in vivo anti-arthritic activity in two animal models. We studied WX486’s metabolic pathway in different species, and evaluated its genotoxicity, MTD, 7 day acute toxicity and 28 day GLP toxicity in rats and dogs. Our studies have shown that WX486 is effective in preclinical animal models, and with high safety window suitable to be developed for rheumatoid arthritis. IND for this indication will be filed with CFDA in early 2016.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.